September 30, 2021
1 min watch
Save
VIDEO: Efficacy shown, toxicity a factor for DS-7300
In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.
"There was efficacy shown, just like with the MGC018, though the toxicity is going to be a key factor of applicability of the agent into clinical practice," Shenderov said.
Published by:
Sources/Disclosures
Collapse
Source:
Johnson ML, et al. Abstract 5130. Presented at: ESMO 2021; Sept. 16-21, 2021 (virtual meeting).
Disclosures:
Shenderov reports receiving clinical trial institutional research funding from MacroGenics; is the founder and CEO of LifeImmune, Inc; and has served as a consultant for Firstthought and Guidepoint Global.
Read more from Take Homes in Prostate Cancer
View allRead more about